Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway

Rietwyk, 2017, Next-generation lipids in RNA interference therapeutics, ACS Nano, 11, 7572, 10.1021/acsnano.7b04734 Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat. Biotechnol., 33, 941, 10.1038/nbt.3330 Semple, 2010, Rational design of cationic lipids for siRNA delivery, Nat Biotechnol, 28, 172, 10.1038/nbt.1602 Love, 2010, Lipid-like materials for low-dose, in vivo gene silencing, Proc. Natl. Acad. Sci. U. S. A., 107, 1864, 10.1073/pnas.0910603106 Dong, 2014, Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates, Proc Natl Acad Sci U S A, 111, 3955, 10.1073/pnas.1322937111 Sato, 2018, Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA, J. Control. Release, 284, 179, 10.1016/j.jconrel.2018.06.017 Sato, 2019, Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo, J. Control. Release, 295, 140, 10.1016/j.jconrel.2019.01.001 Ramaswamy, 2017, Systemic delivery of factor IX messenger RNA for protein replacement therapy, Proc. Natl. Acad. Sci. U. S. A., 114, E1941, 10.1073/pnas.1619653114 Miller, 2017, Non-viral CRISPR/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA, Angew Chem Int Ed Engl, 56, 1059, 10.1002/anie.201610209 Hoy, 2018, Patisiran: first global approval, Drugs, 78, 1625, 10.1007/s40265-018-0983-6 McClellan, 2010, Genetic heterogeneity in human disease, Cell, 141, 210, 10.1016/j.cell.2010.03.032 Wisse, 2008, The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer, Gene Ther., 15, 1193, 10.1038/gt.2008.60 Jacobs, 2010, The role of liver sinusoidal cells in hepatocyte-directed gene transfer, Am. J. Pathol., 176, 14, 10.2353/ajpath.2010.090136 Sato, 2015, Relationship between the physicochemical properties of lipid nanoparticles and the quality of siRNA delivery to liver cells, Mol. Ther. Sato, 2008, Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone, Nat. Biotechnol., 26, 431, 10.1038/nbt1396 Frank-Kamenetsky, 2008, Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc Natl Acad Sci U S A, 105, 11915, 10.1073/pnas.0805434105 Watanabe, 2014, In vivo therapeutic potential of dicer-hunting siRNAs targeting infectious hepatitis C virus, Sci. Rep., 4, 4750, 10.1038/srep04750 Yamamoto, 2016, Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection, J. Hepatol., 64, 547, 10.1016/j.jhep.2015.10.014 Tenzer, 2013, Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology, Nat. Nanotechnol., 8, 772, 10.1038/nnano.2013.181 Hadjidemetriou, 2015, In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles, ACS Nano, 9, 8142, 10.1021/acsnano.5b03300 Hadjidemetriou, 2019, The human in vivo biomolecule corona onto PEGylated liposomes: a proof-of-concept clinical study, Adv. Mater., 31 Akinc, 2010, Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms, Mol. Ther., 18, 1357, 10.1038/mt.2010.85 Yan, 2005, The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse, Biochem. Biophys. Res. Commun., 328, 57, 10.1016/j.bbrc.2004.12.137 Mahley, 1999, Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E, J. Lipid Res., 40, 1, 10.1016/S0022-2275(20)33334-4 Mahley, 1988, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology, Science, 240, 622, 10.1126/science.3283935 Libeu, 2001, New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E, J. Biol. Chem., 276, 39138, 10.1074/jbc.M104746200 Fisher, 1999, Lipid binding-induced conformational changes in the N-terminal domain of human apolipoprotein E, J. Lipid Res., 40, 93, 10.1016/S0022-2275(20)33343-5 Weisgraber, 1983, The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding, J. Biol. Chem., 258, 12348, 10.1016/S0021-9258(17)44181-0 Weisgraber, 1986, Human apolipoprotein E. determination of the heparin binding sites of apolipoprotein E3, J. Biol. Chem., 261, 2068, 10.1016/S0021-9258(17)35898-2 D’Souza, 2015, Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications, J. Control. Release, 203, 126, 10.1016/j.jconrel.2015.02.022 Baenziger, 1980, Human hepatic lectin. Physiochemical properties and specificity, J. Biol. Chem., 255, 4607, 10.1016/S0021-9258(19)85538-2 Connolly, 1982, Binding and endocytosis of cluster glycosides by rabbit hepatocytes. Evidence for a short-circuit pathway that does not lead to degradation, J. Biol. Chem., 257, 939, 10.1016/S0021-9258(19)68290-6 Lee, 1984, New synthetic cluster ligands for galactose/N-acetylgalactosamine-specific lectin of mammalian liver, Biochemistry, 23, 4255, 10.1021/bi00313a037 Nair, 2014, Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing, J Am Chem Soc, 136, 16958, 10.1021/ja505986a Wooddell, 2013, Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection, Mol. Ther., 21, 973, 10.1038/mt.2013.31 Sato, 2012, A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo, J. Control. Release, 163, 267, 10.1016/j.jconrel.2012.09.009 Hashiba, 2017, pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes, J. Control. Release, 262, 239, 10.1016/j.jconrel.2017.07.046 Maeki, 2017, Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers, PLoS One, 12, 10.1371/journal.pone.0187962 Leung, 2015, Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems, J. Phys. Chem. B, 119, 8698, 10.1021/acs.jpcb.5b02891 Mui, 2013, Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles, Mol Ther Nucleic Acids, 2, 10.1038/mtna.2013.66 Chen, 2016, Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA, J. Control. Release, 235, 236, 10.1016/j.jconrel.2016.05.059 Sato, 2016, Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery, J. Control. Release, 229, 48, 10.1016/j.jconrel.2016.03.019 Grefhorst, 2008, Plasma PCSK9 preferentially reduces liver LDL receptors in mice, J. Lipid Res., 49, 1303, 10.1194/jlr.M800027-JLR200 Bertrand, 2017, Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics, Nat. Commun., 8, 777, 10.1038/s41467-017-00600-w Wells, 1998, In vivo clearance of ternary complexes of vitronectin-thrombin-antithrombin is mediated by hepatic heparan sulfate proteoglycans, J. Biol. Chem., 273, 23440, 10.1074/jbc.273.36.23440 Narita, 1995, Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo, J. Biol. Chem., 270, 24800, 10.1074/jbc.270.42.24800 Ji, 1995, Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans, J. Lipid Res., 36, 583, 10.1016/S0022-2275(20)39892-8 Gustafsen, 2017, Heparan sulfate proteoglycans present PCSK9 to the LDL receptor, Nat. Commun., 8, 503, 10.1038/s41467-017-00568-7 Pathak, 1990, Tissue-specific sorting of the human LDL receptor in polarized epithelia of transgenic mice, J. Cell Biol., 111, 347, 10.1083/jcb.111.2.347 Matsuura, 1982, Distribution of an asialoglycoprotein receptor on rat hepatocyte cell surface, J. Cell Biol., 95, 864, 10.1083/jcb.95.3.864 Sato, 2017, Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus, J. Control. Release, 266, 216, 10.1016/j.jconrel.2017.09.044 Zimmermann, 2006, RNAi-mediated gene silencing in non-human primates, Nature, 441, 111, 10.1038/nature04688 Judge, 2009, Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice, J. Clin. Invest., 119, 661, 10.1172/JCI37515 Saito, 2001, Interactions of phosphatidylcholine surface monolayers with triglyceride cores and enhanced ApoA-1 binding in lipid emulsions, Langmuir, 17, 2528, 10.1021/la001583t Nguyen, 2017, Protein corona: a new approach for nanomedicine design, Int. J. Nanomedicine, 12, 3137, 10.2147/IJN.S129300 Innerarity, 1979, Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts, J. Biol. Chem., 254, 4186, 10.1016/S0021-9258(18)50713-4 Foley, 2010, Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins, Prog. Mol. Biol. Transl. Sci., 93, 213, 10.1016/S1877-1173(10)93010-X Aird, 2007, Phenotypic heterogeneity of the endothelium: II. Representative vascular beds, Circ. Res., 100, 174, 10.1161/01.RES.0000255690.03436.ae MacPhee, 1995, Intermittence of blood flow in liver sinusoids, studied by high-resolution in vivo microscopy, Am. J. Phys., 269, G692 Tsoi, 2016, Mechanism of hard-nanomaterial clearance by the liver, Nat. Mater., 15, 1212, 10.1038/nmat4718 Gallagher, 1985, Molecular distinctions between heparan sulphate and heparin. Analysis of sulphation patterns indicates that heparan sulphate and heparin are separate families of N-sulphated polysaccharides, Biochem. J., 230, 665, 10.1042/bj2300665 Roskams, 1995, Heparan sulfate proteoglycan expression in normal human liver, Hepatology, 21, 950, 10.1002/hep.1840210410